Clinical trials: Priming
Angioplasty, Cardiovascular Disease
XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study
Abbott Vascular (AV) obtained marketing approval for the XIENCE PRIME Everolimus Eluting Coronary Stent System (XIENCE PRIME EECSS) in China from the China Food and Drug Administration (CFDA) on August 10th, 2011.
- Conditions
- Angioplasty, Cardiovascular Disease, Coronary Artery Disease, Coronary Heart Disease
- Trial name
- XP China SAS (NCT01894152)
- Testing
- XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
- Where
- United States
- Volunteers
- 2,002 people
- Sponsor
- Abbott Medical Devices
Influenza
Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)
This is a multi-center, randomized, two stage, double-blind, placebo-controlled administration study comprising 200 healthy participants.
- Trial name
- NCT01146119
- Testing
- Multimeric-001, 500 mcg, Adjuvanted PBS, PBS and TIV 15%
- Where
- 2 sites in Israel
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Prostatic Neoplasms
PRIME - PRostate Imaging for Margin Evaluation
This study will evaluate the feasibility of using intra-operative Cerenkov Luminescence Imaging (CLI) of prostatectomy specimens to determine tumour margin status.
- Trial name
- PRIME (NCT02151097)
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Lightpoint Medical Limited
Abdominal Aortic Aneurysm
TriVascular Canadian LIFE Study: Least Invasive Fast-Track EVAR (Endovascular Aneurysm Repair)
The primary objectives of the LIFE Study are to demonstrate the clinical cost and benefits associated with using the Ovation Prime Abdominal Stent Graft System under the least invasive conditions defined in the Fast-Track EVAR…
- Trial name
- NCT02451566
- Testing
- Ovation Prime Abdominal Stent Graft System
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- TriVascular, Inc.
Healthy
A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV administered as heterologous prime-boost vaccine regimens in healthy adult participants.
- Trial name
- NCT02376400
- Testing
- MVA-BN-Filo, Ad26.ZEBOV
- Where
- 2 sites in Tanzania, Uganda
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
ST Elevation Myocardial Infarction
MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction
To evaluate the safety and efficacy of the MGuard™ Prime stent in the treatment of blocked arteries in coronary arteries in patients undergoing a stenting procedure due to having a heart attack.
- Trial name
- MASTER-II (NCT01869738)
- Testing
- MGuard Prime, (BMS/DES)
- Where
- 56 sites in United States, Belgium and 10 more
- Volunteers
- 310 people
- Sponsor
- InspireMD
Meningococcal Immunisation, Healthy Volunteers
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
This study evaluated the immunogenicity and safety of a single dose of MenQuadfi® administered as a booster vaccine in toddlers 12 - 23 months of age in Argentina who had been primed with at least 1 dose of the quadrivalent…
- Trial name
- NCT05929651
- Testing
- MenACYW conjugate vaccine
- Where
- 2 sites in Argentina
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Human Immunodeficiency Virus
A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment
The primary purpose of this study is to assess safety/tolerability of 2 different prime/boost regimens containing adenovirus serotype 26 (Ad26).Mos4.HIV, Modified Vaccinia Ankara (MVA) -Mosaic or adjuvanted Mosaic and Clade C…
- Trial name
- NCT03307915
- Testing
- Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Janssen Vaccines & Prevention B.V.
Infections, Meningococcal
Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration
The purpose of this study is to demonstrate, in 12-23 months old subjects, the non-inferiority of meningococcal vaccine GSK134612 and pneumococcal vaccine GSK1024850A when co-administered, compared to each vaccine administered…
- Trial name
- NCT00758264
- Testing
- Meningococcal vaccine GSK134612, Pneumococcal vaccine GSK1024850A
- Where
- 5 sites in Mexico, Taiwan
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Metabolic Syndrome, Anxiety
PRebiotic Intervention for Metabolic and MEntal Health (PRIME)
The purpose of the study is to determine whether a daily prebiotic fibre blend can reduce systemic inflammation, dyslipidemia, and self-report measures of mental health in individuals with metabolic syndrome.
- Conditions
- Metabolic Syndrome, Anxiety, Mood, Stress
- Trial name
- PRIME (NCT06216626)
- Testing
- myota's prebiotic fibre blend
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Myota GmbH
Infections, Streptococcal
Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children
The objective of this study is to evaluate the immune memory through the administration of an additional dose of GSK Biologicals' pneumococcal conjugate vaccine GSK1024850A, the antibody persistence and long-term effect on…
- Trial name
- NCT00950833
- Testing
- Pneumococcal vaccine GSK1024850A
- Where
- 10 sites in Czechia
- Volunteers
- 466 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia, Pneumococcal, Diabetes Mellitus
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
Primary care visits are a key aspect of clinical care focused on helping patients to close care gaps related to preventive care such as vaccination, diabetes testing, statin therapy and cancer screening.
- Conditions
- Pneumonia, Pneumococcal, Diabetes Mellitus, Breast Cancer, Colorectal Cancer
- Trial name
- NCT05799976
- Testing
- Text message nudge
- Where
- United States
- Volunteers
- 29,334 people, healthy volunteers welcome
- Sponsor
- Mitesh Patel
Infections, Streptococcal
Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule
This is a booster study in 2 groups of healthy children less than 3 years old to measure the reactogenicity, safety and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine, when given as a booster or as a two-dose…
- Trial name
- NCT00513409
- Testing
- Synflorix, Infanrix Hexa, Havrix
- Where
- Chile
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vascular Disease, Myocardial Ischemia
A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese Population
The purpose of this study is to evaluate the safety and effectiveness of the AVJ-09-385 Small Vessel Everolimus Eluting Coronary Stent System (EECSS) (2.25 mm diameter stent) in treatment of subjects with ischemic heart disease…
- Conditions
- Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease
- Trial name
- SV JAPAN (NCT01115933)
- Testing
- XIENCE PRIME SV EECSS
- Where
- 14 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Abbott Medical Devices
Diphtheria, Tetanus
DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants
The aim of this study is to evaluate the immunogenicity and safety of a novel DTaP-IPV-Hep B-PRP~T fully liquid combined hexavalent vaccine (study vaccine) administered at 2, 4, and 6 months of age compared to Sanofi Pasteur's…
- Conditions
- Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b Infection
- Trial name
- NCT02094833
- Testing
- DTaP-IPV-Hep B-PRP~T combined vaccine, DTaP-IPV//PRP~T and Hepatitis B vaccine
- Where
- 16 sites in South Korea
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Streptococcus Pneumoniae
Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar
The present study intends to investigate the use as a booster of a dose of sanofi pasteur's Pneumo 23 vaccine in the second year of life following 3-dose priming with Wyeth's Prevnar vaccine.
- Trial name
- NCT00594347
- Testing
- Pneumo 23, Prevnar
- Where
- 2 sites in Thailand
- Volunteers
- 339 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Cardiac Surgical Procedures, Extracorporeal Circulation; Complications
Acute Kidney Injury After Cardiac Surgery
PrimECC is a colloid priming solution for cardiopulmonary bypass/ extracorporeal circulation (ECC) based on Ringers Lactate, supplmeneted with Dextran 40 and Dextran 1.
- Conditions
- Cardiac Surgical Procedures, Extracorporeal Circulation; Complications, Acute Kidney Injury
- Trial name
- NCT04293744
- Testing
- Colloid priming solution for ECC circuit, Standard priming solution for ECC circuit
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- XVIVO Perfusion
ST Elevation Myocardial Infarction
MGuard™ Prime Embolic Protection Stent in Patients With Acute ST Elevation Myocardial Infarction
Prospective, non-randomized, single arm, multicenter observational study. The objective is to evaluate the safety and efficacy of the MGuard™ Prime stent in the treatment of de novo stenotic lesions in coronary arteries in…
- Trial name
- e-MASTER (NCT02292823)
- Testing
- MGuard™ Prime Embolic Protection Stent System
- Where
- Netherlands
- Volunteers
- 63 people
- Sponsor
- InspireMD
Infections, Streptococcal
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine
This study will evaluate the safety, reactogenicity and immunogenicity of a booster dose of the pneumococcal conjugate vaccine, co-admin with a 1st dose or a 2nd dose of MMRV vaccine at 12-14 or respectively 14-16 months of age…
- Trial name
- NCT00370227
- Testing
- 10 valent pneumococcal conjugate (vaccine)
- Where
- 8 sites in Finland
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Cancer
SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection
The goal of this clinical trial is to evaluate the safety profile and tolerability of SDT-M001 injection in NSCLC patients with driver-gene-negative and negative PD-L1 expression after radical surgical resection; to determine the…
- Trial name
- NCT07096882
- Testing
- SDT-M001 injection
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Cytocraft Biopharmaceutical Co., Ltd.